Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -55.82% is 14% above its 2-year average of -65.00%, around the middle of its 2-year range (-109.89%–-21.18%).
8.45% below its 12-month average of -51.47%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -24.57%.
NET PROFIT MARGIN
-55.82%
NET PROFIT MARGIN AVG TTM
-51.47%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-8.45%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Heartflow, Inc. Common Stock
Market Cap
$4.65B
Net Profit Margin
-55.82%
TTM Avg
-51.47%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.75B
Net Profit Margin
3.19%
TTM Avg
-1.95%
3Y Avg
-11.66%
5Y Avg
-17.12%
Market Cap
$4.81B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.46B
Net Profit Margin
26.65%
TTM Avg
8.56%
3Y Avg
0.11%
5Y Avg
0.58%
Market Cap
$4.87B
Net Profit Margin
-1570.85%
TTM Avg
-4668.05%
3Y Avg
-2830.27%
5Y Avg
-2034.87%
Market Cap
$4.88B
Net Profit Margin
-20.73%
TTM Avg
-55.30%
3Y Avg
-87.73%
5Y Avg
-105.64%
Market Cap
$4.33B
Net Profit Margin
-248.83%
TTM Avg
-379.86%
3Y Avg
-278.01%
5Y Avg
-170.03%
Market Cap
$4.29B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Heartflow, Inc. Common Stock (HTFL) | $4.65B | -55.82% | -51.47% | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.75B | 3.19% | -1.95% | -11.66% | -17.12% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | 0.00% | 0.00% | 0.00% | 0.00% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.46B | 26.65% | 8.56% | 0.11% | 0.58% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.87B | -1570.85% | -4668.05% | -2830.27% | -2034.87% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.88B | -20.73% | -55.30% | -87.73% | -105.64% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.33B | -248.83% | -379.86% | -278.01% | -170.03% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.29B | 0.00% | 0.00% | 0.00% | 0.00% |
| Erasca, Inc. (ERAS)vs › | $5.06B | 0.00% | 0.00% | 0.00% | 0.00% |
| LivaNova PLC (LIVN)vs › | $4.21B | 12.82% | -6.21% | -4.84% | -11.63% |
Operating Margin
-34.3%
Net Profit Margin
-55.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -24.57% |
| 2026-03-31 | -52.07% |
| 2025-12-31 | -49.65% |
| 2025-09-30 | -109.89% |
| 2025-06-30 | -21.18% |
| 2025-03-31 | -86.94% |
| 2024-12-31 | -94.28% |
| 2024-09-30 | -58.12% |
| 2024-06-30 | -75.28% |
| 2024-03-31 | -77.98% |
